(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
New funding transforms lives by expanding electricity access across Africa - 2Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- 3the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- 4Palestinians protest against Israel's new death penalty law
- 5Going with Children: Tips for Tranquil Family Get-aways
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Building a Maintainable Closet: Individual Excursions in Moral Style
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
